×
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

$6.88
+0.01 (+0.15%)
(As of 05/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.62
$6.94
50-Day Range
$6.51
$8.57
52-Week Range
$4.81
$8.65
Volume
998,251 shs
Average Volume
1.16 million shs
Market Capitalization
$707.13 million
P/E Ratio
16.38
Dividend Yield
N/A
Beta
1.29
30 days | 90 days | 365 days | Advanced Chart
Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Catalyst Pharmaceuticals logo

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Sales & Book Value

Annual Sales
$140.83 million
Cash Flow
$0.39 per share
Book Value
$2.14 per share

Profitability

Net Income
$39.48 million
Pretax Margin
39.19%

Debt

Price-To-Earnings

Miscellaneous

Free Float
89,624,000
Market Cap
$707.13 million
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/25/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.58 out of 5 stars

Medical Sector

97th out of 1,421 stocks

Pharmaceutical Preparations Industry

36th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

Is Catalyst Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals
or view top-rated stocks.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 7,450,000 shares, an increase of 45.8% from the April 30th total of 5,110,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 6.4 days. Approximately 7.8% of the company's stock are sold short.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Catalyst Pharmaceuticals
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by $0.02. The biopharmaceutical company earned $43.09 million during the quarter, compared to analyst estimates of $43.17 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 23.95% and a net margin of 29.31%. During the same quarter in the previous year, the firm posted $0.09 EPS.
View Catalyst Pharmaceuticals' earnings history
.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $195.00 million-$205.00 million, compared to the consensus revenue estimate of $199.99 million.

What price target have analysts set for CPRX?

4 brokers have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their forecasts range from $8.75 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $10.92 in the next twelve months. This suggests a possible upside of 58.7% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 75, Pay $928.18k) (LinkedIn Profile)
  • Ms. Alicia Grande, Chief Accounting Officer, VP, Treasurer & CFO (Age 51, Pay $558.27k)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 60, Pay $667.17k)
  • Dr. Gary Ingenito, Chief Medical & Regulatory Officer (Age 66, Pay $639.29k) (LinkedIn Profile)
  • Mr. Jeffrey Del Carmen, Chief Commercial Officer (Age 51, Pay $507.96k)
  • Ms. Mary Coleman, VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D., Chief Compliance Officer & Chief Legal Officer (Age 58)
  • Mr. Pete Curry Sr., VP of Sales
  • Dr. Preethi Sundaram Ph.D., Chief Strategy Officer (Age 46)
  • Mr. Philip B. Schwartz, Corp. Sec. (Age 67)
What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.24%), Vanguard Group Inc. (4.61%), State Street Corp (4.49%), LSV Asset Management (3.60%), Royce & Associates LP (2.20%) and Dimensional Fund Advisors LP (2.09%). Company insiders that own Catalyst Pharmaceuticals stock include Alicia Grande, Charles B O'keeffe, Gary Ingenito, Patrick J Mcenany, Philip H Coelho and Steve Miller.
View institutional ownership trends for Catalyst Pharmaceuticals
.

Which institutional investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, LSV Asset Management, Royce & Associates LP, BlackRock Inc., Citigroup Inc., SG Americas Securities LLC, Vanguard Group Inc., and Renaissance Technologies LLC. Company insiders that have sold Catalyst Pharmaceuticals company stock in the last year include Alicia Grande, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, and Steve Miller.
View insider buying and selling activity for Catalyst Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was bought by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Hillsdale Investment Management Inc., Friess Associates LLC, Invesco Ltd., Goldman Sachs Group Inc., Victory Capital Management Inc., Dimensional Fund Advisors LP, and Quantedge Capital Pte Ltd. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $6.88.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals has a market capitalization of $707.13 million and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.42 on an earnings per share basis.

How many employees does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals employs 76 workers across the globe.

When was Catalyst Pharmaceuticals founded?

Catalyst Pharmaceuticals was founded in 2002.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at [email protected], or via fax at 305-529-0933.

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.